NUVL - Nuvalent, Inc.

100.22
-1.070   -1.068%

Share volume: 475,751
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$101.29
-1.07
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 20%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.70%
1 Month
-4.54%
3 Months
-6.21%
6 Months
25.79%
1 Year
39.95%
2 Year
17.91%
Key data
Stock price
$100.22
P/E Ratio 
0.00
DAY RANGE
$97.24 - $102.03
EPS 
-$5.54
52 WEEK RANGE
$55.54 - $113.02
52 WEEK CHANGE
$39.21
MARKET CAP 
7.314 B
YIELD 
N/A
SHARES OUTSTANDING 
78.617 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
1.31
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$522,988
AVERAGE 30 VOLUME 
$499,487
Company detail
CEO: James R. Porter
Region: US
Website: nuvalent.com
Employees: 40
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations.

Recent news